| Literature DB >> 28936210 |
Reyin Lien1, Yung-Feng Lin2, Min-Wei Lai3, Hui-Ying Weng4, Ren-Chin Wu5, Tang-Her Jaing6,7, Jing-Long Huang6,8, Shih-Feng Tsai2, Wen-I Lee6,8.
Abstract
The gastrointestinal tract contains the largest lymphoid organ to react with pathogenic microorganisms and suppress excess inflammation. Patients with primary immunodeficiency diseases (PIDs) can suffer from refractory diarrhea. In this study, we present two siblings who began to suffer from refractory diarrhea with a poor response to aggressive antibiotic and immunosuppressive treatment after surgical release of neonatal intestinal obstruction. Their lymphocyte proliferation was low, but superoxide production and IL-10 signaling were normal. Candidate genetic approach targeted to genes involved in PIDs with inflammatory bowel disease (IBD)-like manifestation was unrevealing. Whole-genome sequencing revealed novel heterozygous mutations Glu75Lys and nucleotide 520-521 CT deletion in the tetratricopeptide repeat domain 7A (TTC7A) gene. A Medline search identified 49 patients with TTC7A mutations, of whom 20 survived. Their phenotypes included both multiple intestinal atresia (MIA) and combined T and/or B immunodeficiency (CID) in 16, both IBD and CID in 14, isolated MIA in 8, MIA, IBD, and CID complex in 8, and isolated IBD in 3. Of these 98 mutant alleles over-through the coding region clustering on exon 2 (40 alleles), exon 7 (12 alleles), and exon 20 (10 alleles), 2 common hotspot mutations were c.211 G>A (p.E71K in exon 2) in 26 alleles and AAGT deletion in exon 7 (+3) in 10 alleles. Kaplan-Meier analysis showed that those with biallelic missense mutations (p = 0.0168), unaffected tetratricopeptide repeat domains (p = 0.0311), and developing autoimmune disorders (p = 0.001) had a relatively better prognosis. Hematopoietic stem cell transplantation (HSCT) restored immunity and seemed to decrease the frequency of infections; however, refractory diarrhea persisted. Clinical improvement was reported upon intestinal and liver transplantation in a child with CID and MIA of unknown genetic etiology. In conclusion, patients with TTC7A mutations presenting with the very early onset of refractory diarrhea had limit improvement by HSCT or/and tailored immunosuppressive therapy in the absence of suitable intestine donors. We suggest that MIA-CID-IBD disorder caused by TTC7A mutations should also be included in the PID classification of "immunodeficiencies affecting cellular and humoral immunity" to allow for prompt recognition and optimal treatment.Entities:
Keywords: combined T and B immunodeficiency; inflammatory bowel disease; multiple intestinal atresia; refractory diarrhea; tetratricopeptide repeat domain 7A
Year: 2017 PMID: 28936210 PMCID: PMC5594067 DOI: 10.3389/fimmu.2017.01066
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1(A) Gastric outlet obstruction was identified in an upper gastrointestinal barium series as demonstrated during a surgical intervention showing (B) a grossly intraluminal nodule and (C) a duodenal web-like structure.
Figure 2Photomicrographs of the ileum and colon (hematoxylin and eosin). (A) The terminal ileum of patient 1 showed erosion, severely inflamed mucosa, and a lack of Peyer’s patches (2× objective). (B) Widespread crypt abscesses (arrowheads) were noted in association with crypt destruction (10× objective). (C) The lamina propria was infiltrated by neutrophils and eosinophils with few lymphocytes. Apoptotic bodies (arrowheads) were frequently found in the crypt epithelia (40× objective). (D) The colon mucosa of patient 2 showed marked crypt epithelial hyperplasia and frequent apoptosis (arrowheads).
Figure 3At 1 day of age, congenital pyloric atresia and narrow thymus shadow in her middle mediastinum were noted on a plain X-ray.
Hematogram and basic immunologic evaluations in our two female siblings.
| Patient 1 | Patient 2 | |||
|---|---|---|---|---|
| Age (normal range) | 1 day | 2 months | 7 days | 3 months |
| WBC (6,000–17,500/mm3) | 15,400 | 10,900 | 13,400 | |
| Segment (6,000–8,500/mm3) | 7,848 | |||
| Lymphocyte (2,000–13,500/mm3) | 9,176 | |||
| Hb (>10 mg/dL) | 17.7 | 10.7 | 10.5 | |
| Platelet (>150/mm3) | 231 | 563 | ||
| AST (13–40 U/L) | 42 | 23 | 46 | |
| ALT (<36 U/L) | 9 | 6 | 36 | |
| Albumin (>3.5 mg/dL) | ||||
| BUN (5–20 mg/dL) | 6.6 | 8.0 | 8.1 | 7.8 |
| Cr (0.2–1.0 mg/dL) | 0.5 | 0.1 | 0.5 | 0.1 |
| CRP (<5 mg/dL) | <5 | |||
| CD3 (51–84) | 60.1 | 80.3 | 94.8 | |
| CD4 (31–56) | 32.5 | 33.3 | 16.0 | |
| CD8 (12–35) | 23,7 | 48.9 | 60.3 | |
| CD19 (6–27) | 20.8 | 15.2 | ||
| CD19CD27 B memory (0.5–2.4) | 0.54 | |||
| CD4CD45RA naïve T (12–45) | 27.7 | 31.4 | ||
| CD4CD45RO T memory (3–26) | 5.4 | 12.2 | 5.6 | |
| CD8CD45RO T memory (1–11) | 1.0 | |||
| Activated CD3HLADR T cells (4–26) | 4.2 | |||
| Natural killer CD16CD56 cells (3–19) | 18.2 | 3.1 | ||
| IgM (49–156 mg/dL) | 62.7 | |||
| IgG (334–1,230 mg/dL) | ||||
| IgG2 (30–140 mg/dL) | 50 | |||
| IgA (15–113 mg/dL) | 39 | |||
| IgE (<100 IU/mL) | <17.8 | <17.8 | ||
| PHA 2.5 μg/mL (29,228–58,457) | ||||
| PWM 0.1 μg/mL (11,395–28,487) | ||||
| BCG 0.002 μg/mL (1,740–4,352) | ||||
| (88–99%) | 94.5 | 87.4 | ||
| (4.7–21.4%) | 8.6 | 9.7 | ||
PHA, phytohemagglutinin; cpm, counts per minute; .
Figure 4Sanger sequencing showed the heterozygous compound tetratricopeptide repeat domain 7A mutation: c.223 G>A in exon 2 causing Glu75Lys from the maternal allele and c.520-521 del CT fs174 × 27 in exon 4 from the paternal allele.
Figure 5(A) Survival curve of the five phenotypes by Kaplan–Meier analysis showed (B) the significantly higher median lifespan in those with MIA + CID (median: 19 months), IBD + CID (168 months), and MIA + IBD + CID (11.5 months) compared to those with MIA alone (0.17 months); and also marginally significant with IBD + CID compared to MIA + CID. Abbreviations: MIA, multiple intestinal atresia; CID, combined T and B cell immunodeficiency; IBD, inflammatory bowel disease.
Mortality and mutation patterns associated with the five phenotypes in patients with TTC7A mutations.
| Phenotype | Total | MIA + CID | IBD + CID | MIA | MIA + IBD + CID | IBD |
|---|---|---|---|---|---|---|
| Patient number | 49 | 16 | 14 | 8 | 8 | 3 |
| Both missense | 2 | 14 | 0 | 0 | 2 | |
| Others | 14 | 0 | 8 | 8 | 1 | |
| Sepsis | 10 | 4 | 2 | 2 | 1 | 1 |
| Intestinal obstruction | 8 | 1 | 1 | 5 | 1 | |
| Viral pneumonia | 4 | 2 | 2 | |||
| HSCT | 2 | 2 | ||||
| Pulmonary emboli | 1 | 1 | ||||
| Pulmonary hemorrhage | 1 | 1 | ||||
| Cardiac arrest | 1 | 1 | ||||
| Gastric carcinoma | 1 | 1 | ||||
| Hepatic failure | 1 | 1 | ||||
| Cases of mortality | 29 | 10 | 6 | 7 | 5 | 1 |
MIA, multiple intestinal atresia; CID, combined T and B cell immunodeficiency; IBD, inflammatory bowel disease; HSCT, hematopoietic stem cell transplantation; TTC7A, tetratricopeptide repeat domain 7A.
Figure 6We analyzed their prognosis in the presence of genetic bi-missense mutations (A), tetratricopeptide repeat (TPR) domain involvement (B), autoimmune disorders (C), and hematopoietic stem cell transplantation (HSCT) (D) by Kaplan–Meier analysis, which revealed a significantly better prognosis in those with bi-missense mutations (p = 0.0168), without TPR domains (p = 0.0311), and with autoimmune disorders (p = 0.001), but not significantly in those receiving HSCT (p = 0.9084).